Genfit up on Fast Track for NASH compound

Genfit S.A. (Euronext:ALGFT) jumped EUR 7.07 (34%) to EUR 28.02 on Tuesday after FDA granted Fast Track designation to the company's GFT505 to treat non-alcoholic steatohepatitis (NASH), a liver condition with no approved treatments. The dual peroxisome proliferation activated receptor (PPAR) alpha and delta agonist is in the pivotal Phase IIb GFT505-212-7 trial in the indication, with data expected at year end. ...